Journal
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 27, Issue 12, Pages 3758-3768Publisher
AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2015101142
Keywords
-
Categories
Funding
- Abbott Laboratories (Alameda, CA)
- Abbvie
- Alexion
- Amgen, Inc. (Thousand Oaks, CA)
- American Society of Nephrology
- AstraZeneca Pharmaceuticals (Wilmington, DE)
- AVEO
- Chugai Pharmaceutical Co (Tokyo, Japan)
- DaVita, Inc.
- Fresenius
- Genetech
- Haymarket Media
- Hospira
- Kabi
- Keryx
- National Institutes of Health
- National Kidney Foundation
- Relypsa
- Resverlogix
- Sanofi US (Bridgewater, NJ)
- Shire
- Vifor
- ZS Pharma
Ask authors/readers for more resources
In patients with ESRD, residual kidney function (RKF) contributes to achievement of adequate solute clearance. However, few studies have examined RKF in patients on hemodialysis. In a longitudinal cohort of 6538 patients who started maintenance hemodialysis over a 4-year period (January 2007 through December 2010) and had available renal urea clearance (CLurea) data at baseline and 1 year after hemodialysis initiation, we examined the association of annual change in renal CLurea rate with subsequent survival. The median (interquartile range) baseline value and mean SD annual change of CLurea were 3.3 (1.9-5.0) and-1.1 +/- 2.8 ml/min per 1.73 m(2), respectively. Greater CLurea rate 1 year after hemodialysis initiation associated with better survival. Furthermore, we found a gradient association between loss of RKF and all-cause mortality: changes in CLurea rate of -6.0 and +3.0 ml/min per 1.73 m(2) per year associated with case mix-adjusted hazard ratios (95% confidence intervals) of 2.00 (1.55 to 2.59) and 0.61 (0.50 to 0.74), respectively (reference: -1.5 ml/min per 1.73 m(2) per year). These associations remained robust against adjustment for laboratory variables and ultra filtration rate and were consistent across strata of baseline CLurea, age, sex, race, diabetes status, presence of congestive heart failure, and hemoglobin, serum albumin, and serum phosphorus levels. Sensitivity analyses using urine volume as another index of RKF yielded consistent associations. In conclusion, RKF decline during the first year of dialysis has a graded association with all-cause mortality among incident hemodialysis patients. The clinical benefits of RKF preservation strategies on mortality should be determined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available